Cantargia reports opposition against recently granted European patent
Cantargia AB reported today that oppositions have been filed against one of Cantargia’s European patents, EP3293202. This patent provides a broad protection for IL1RAP-targeting antibodies with similar properties as nadunolimab. Cantargia holds a large number of granted patents related to IL1RAP-targeting therapies. The oppositions have no formal impact on Cantargia’s other patents, including those specifically covering nadunolimab.Cantargia has extensive patent protection for IL1RAP-targeting antibodies, through over 100 granted patents globally including therapy and diagnostics of cancer.